Upload
vankhanh
View
228
Download
3
Embed Size (px)
Citation preview
262
Further preclinical and clinical trials are required to warrantee
the used of the dosage form in human beings.
The study was performed to check the release retarding
properties of the natural polymer used. It is further recommend
for future research for dose calculation for matrix transdermal
patches.
The pharmacodynamics studies to be established in diabetic
animals
A detailed pre-clinical data is yet to be established to find out
flux, lag time etc.
The study can be extrapolated to clinical trials. Since the
polymers used are of natural origin with maximum safety
7. REFERENCES
1. Insulin and Oral Anti diabetic Drug. In Satoskar RS,
Bhandarkar SD, Ainapure SS., Pharmacology and
Pharmacotherapeutics. Popular Prakashan; 2000; 874,
889,900-901.
2. Insulin and Oral Hypoglycemic Agents. In Brody, Larner,
Minneman. Human Pharmacology, Mosby Publications 1995,
541-51.
3. Oral Hypoglycemic drug. In Hardman JG, Limbira LE, Gilman
AG. Goodman and Gilman The pharmacological Basis of
Therapeutics, New York: McGraw Hill Medical Publishing
Division, 2001; 1586-87.
4. Diabetes Mellitus. In Walker R, Edwards C, Clinical Pharmacy
and Therapeutics, 2nd edition, Churchill Livingstone: 633-637.
263
5. Insulin and Oral Hypoglycemic Agents. In Barar FSK, Essentials
of Pharmacotherapeutics, S. Chand and Co. Ltd., New Delhi:
548-56.
6. Insulin, Oral hypoglycemic drug and glucagon. In: Tripathy KD,
Essentials of Medical Pharmacology, New Delhi: Jaypee Brother,
Medical Publishers (P) Ltd., 2003; 335-53.
7. Benett PH. Diabetes: Definition and Pathogenesis. In: Ronald
Kahn C, Weir GC, Joslin‘s Diabetes Mellitus. 13th ed. New Delhi:
Waverly Private Limited; 1996. 193-7.
8. Gandhi T.P. 1978, Sulphonylureas – Second Generation Drugs
Indian Drugs 6: 1978, 163-65.
9. Hypoglycemics in Elderly Patients. J. Clin. Pharm. Ther., 21(4):
243-245
10. Chien YW, Concepts and system design for rate-controlled drug
delivery in novel drug delivery systems. 2nd edn, New York:
Marcel Dekker Inc.; 1992, 50:1-42.
11. Chiao CS, Robinson JR. Sustained-release drug delivery
systems. Remington: The Science and Practice of Industrial
Pharmacy. 19th edn. Eastern Pennsylvania. Mack Publication
Company; Vol.II, 1995, 1660-75
12. Khan GM. Controlled release oral dosage forms: Some recent
advances in matrix type drug delivery systems. The Sciences;
1(5): 2001, 350-4.
13. Lee TW, Robinson R. Controlled release drug delivery systems.
Gennaro AR, Remington: The science and practice of pharmacy.
264
20th ed. Vol.1, Philadelphia: Lippincott Williams and Wilkinson;
2000.903-28.
14. Lalla JK. Introduction to oral controlled drug delivery systems.
The Eastern Pharmacist; 45: 1991, 25-28
15. Thanoo BC, Sunny MC, Jayakrishnan A. Oral sustained-release
drug delivery systems using polycarbonate microspheres
capable of floating on gastric fluid. J Pharm Pharma col; 45:
1993, 21-24
16. Aulton ME. Pharmaceutics: The Science of dosage form design.
International Student edition. London: Churchill Livingstone
2002; 206-211.
17. Wab H, Robinson JR, Lee VHL. Design of oral controlled release
drug delivery systems. In: Robinson VR, Lee VHL. Controlled
Drug Delivery Fundamentals and Applications, second edition,
New York, Marcel Dekker 1987; 418-420.
18. Lapidus H, Lordi NG, Drug Release from Compressed
Hydrophilic Matrices, J. Pharm. Sci.; 57(8): 1968, 1292-1301.
19. Heller J, Use of Polymers in controlled release of active agents,
controlled drug delivery. Fundamentals and applications, J R
Robinson, V H L Lee, Marcel Dekker; New York, 1987:179-212
20. Nandita GD, Sudip KD. Controlled-release of oral dosage forms,
Formulation, Fill and Finish 2003, 10-16
21. Ratner BD, Kwok C. Characterization of delivery systems,
surface analysis and controlled release systems. In:
265
Encyclopaedia of Controlled Drug Delivery, Vol-I. Published by
John Wiley & sons. 1999; 349-362.
22. Vyas SP, Khar RK. Controlled Drug Delivery: Concepts and
Advances. 1st ed. vallabh prakashan, 2002, 156-189.
23. Landsberg L and Young JB, Physiology and Pharmacology of the
Autonomic Nervous System, in Harrison‘s Principles of Internal
Medicine (Eds. E. Braunwald, A. S. Fanci, D. L. Kasper, S. L.
Hauser, D. L. Longo and J. L. Janeson), 15th ed., Mc. Graw Hill,
New York 2001,447.
24. Rawat S, Vengurlekar S, Rakesh B, Jain S, Srikarti G.
Transdermal delivery by iontophoresis. Indian J Pharm Sci; 70:
2008, 5-10.
25. Wade Hull MS, Heat-enhanced transdermal drug delivery: A
survey paper, J Appl Res; 2: 2002, 1-9.
26. Jain S, Jain P, Jain NK. Transfersomes: a novel vesicular
carrier for enhanced transdermal delivery: development,
characterization and performance evaluation. Drug Dev Ind
Pharm.; 29: 2003, 1013-1026.
27. Wertz PW, Downing DT, In: Transdermal drug delivery;
developmental issues and research iniatives. Hadgraft J, Guy
RH, Eds. Marcel Dekker Inc.: New York. 1989, 1-22.
28. Baichwal MR. Polymer films as drug delivery systems. In:
Advances in drug delivery systems, Bombay, MSR Foundation;
1985,136-147.A
266
29. Kandavilli S, Nair V, Panchagnula R. Polymers in transdermal
drug delivery systems, Pharmaceutical Technology 2002, 62-78
30. Chien YW, Valia KH. Development of a dynamic skin
permeation system for long term studies. Drug Dev Ind Pharm.;
10: 1984, 575-599.
31. Waiters KA. Penetration enhancers and their use in
Transderinal Therapeutic Systems, in Transdennal Drug
Delivery, Volume 35, Drugs and the Pharmaceutical Sciences
Marcel Dekker, 1989
32. Heather AE. Transdermal Drug Delivery: Penetration
Enhancement Techniques, Current Drug Delivery; 2, 2005, 23-
33
33. Stoughton R. Enhanced percutaneous penetration with 1-
dodecylazacycloheptan-2-one. Arch. Dermatol., 1982, 118: 474-
477.
34. Wertz, P.W.; Downing, D.T., In Transdermal drug delivery:
developmental issues and research iniatives, Hadgraft, J.; Guy,
R.H., Eds. Marcel Dekker Inc.: New York. 1989, 1-22.
35. Chien YW. Development of transdermal drug delivery
system. Drug Dev Ind Pharm. 13: 1987, 589-651.
36. Prausnitz MR, Mitragotri S, Langer R. Current status and future
potential of transdermal drug delivery. Nature Reviews, Drug
Discovery, 3: 2004, 115-124.
267
37. Katz M, Poulsen BJ, In Handbook of Experimental
Pharmacology, Brodie, B.B.; Gilette, J., Eds. Springer Verlag:
Berlin. 1971, 103-174.
38. Kumar, Ritesh, Philip, Anil. Modified Transdermal Technologies:
Breaking the Barriers of Drug Permeation via the Skin; Tropical
Journal of Pharmaceutical Research 6 (1): 2007, 633-644.
39. Jain N, Talegonkar S, Jain N K. New ways to enter the blood
stream: Emerging strategies in transdermal drug delivery. The
Pharma Review, 2004: 41- 59
40. Arcangelo, Virginia P. Peterson, Andrew M.;
Pharmacotherapeutics for Advanced Practice, Published by
Lippincott Williams & Wilkins, 2005, 74.
41. Tripathi KD. Essentials of Medical Pharmacology. 4th ed. New
Delhi: Medical Publishers (p) Ltd.; 1999, 142-44.
42. Kahn CR, Shechter Y. Oral hypoglycemic agents and the
pharmacology of the endocrine pancreas. In: Theodore WR, Alan
SN, Taylor P, Gilman AG, eds. Goodman and Gilman‘s The
Pharmacological Basis of Therapeutics. 8th ed. New York, NY:
McGraw-Hill; 1991, 1484.
43. Shahla Jamzad and Reza Fassihi, Development of a controlled
release low dose class II drug-Glipizide, International Journal of
Pharmaceutics, 312: 2006, 24–32.
44. Bhosale Ashok V, Hardikar Sharwaree R, Jagtap Rajesh S, Patil
Naresh B, Dhawale Sushant S, Shirsath Sanjay C, Formulation
Of Beta Cyclodextrin Complexed Controlled Release Matrix
268
Tablet Of Glipizide And Its In-Vitro Evaluation, International
Journal of PharmTech Research, 1 (3): 2009, 773-778.
45. Hosmani AH, Kasture PV, Gonjari ID, Karmarkar AB, Study of
formulation variables on properties of glipizide mucoadhesive
microspheres by factorial design, DARU, 17 (4): 2009.
46. Chowdary KPR and Rao YS. Design and In vitro and In vivo
Evaluation of Mucoadhesive Microcapsules of Glipizide for Oral
Controlled Release: A Technical Note. AAPS PharmSciTech. 4(3):
2003, 159-168, article 39.
47. Hagalavadi Nanjappa Shivakumar, Pragnesh Bharat Patel
Bapusaheb Gangadhar Desai, Purnima Ashok, Sinnathambi
Arulmozhi, Design and statistical optimization of glipizide
loaded lipospheres using response surface methodology, Acta
Pharm. 57 , 2007, 269–285.
48. Patel JK, Patel RP, Amin AF, Patel MM, Formulation and
Evaluation of Mucoadhesive Glipizide Microspheres. AAPS
Pharm SciTech.; 6(1): 2005, 49-55.
49. Bennett N, Papich MG, Hoenig M, Fettman MJ, Lappin MR.,
Evaluation of transdermal application of glipizide in a pluronic
lecithin gel to healthy cats. Am J Vet Res. 66(4): 2005, 581-588.
50. Ouyang D, Nie S, Li W, Guo H, Liu H and Pan W, Design and
evaluation of compound metformin/glipizide elementary osmotic
pump tablets. The Journal of pharmacy and pharmacology (J
Pharm Pharmacol), 57 (7), 2005, 817-20.
269
51. Radhikaa PR, Pala TK and Sivakumar T, Formulation and
Evaluation of Sustained Release Matrix Tablets of Glipizide,
Iranian Journal of Pharmaceutical Sciences, 2009: 5(4), 205-
214.
52. Thombre AG, De Noto AR and Gibbes DC. Delivery of glipizide
from asymmetric membrane capsules using encapsulated
excipients, J. Control. Rel. 60 (2-3): 1999, 333-341.
53. Jolly MS, Mayur GS and Rajashree CM. Drug release and
swelling kinetics of directly compressed glipizide sustained-
release matrices: Establishment of level A IVIVCJournal of
Controlled Release, 129 (1, 2), 2008, 49-58.
54. Kajal Ghosal, Rajan R and Nanda A. Effects of Chemical
Enhancers on the Release of Glipizide through matrix Patch,
International Journal of ChemTech Research, 1 (4): 2009, 1128-
1130.
55. Mona samalty. Determination of Glimepiride, Glibenclamide,
and related substances using monolithic column and flow
program, Journal of separation science, 13 (9): 1998, 586-597.
56. Chowdary KPR and Balatripura Sundari G, Design And
Evaluation Of Mucoadhesive Controlled Release Oral Tablets Of
Glipizide, 65 (6): 2003, 591-594.
57. Srinivas Mutalik, Nayanabhirama Udupa, Sharath Kumar, Sunil
Agarwal, Ganesh Subramanian and Averineni KR. Glipizide
matrix transdermal systems for diabetes mellitus: Preparation,
270
In vitro and preclinical studies, Life Sciences, 79 (16), 2006,
1568-1577.
58. Ammar HO, Salama HA, Ghorab M, El-Nahhas SA, Elmotasem
HA. Transdermal Delivery System for Glipizide, Current Drug
Delivery, 3 (3): 2006, 333-341.
59. Ke-Shu Yan, Ting-Xu Yan, Hong Guo, Ji-Zhong Li, Lan-Lan Wei,
Chao Wang, Shu-Fang Nie, Wei-San Pan, Evaluation of
transdermal permeability of pentoxifylline gel: In vitro skin
permeation and In vivo microdialysis using Wistar rats, Drug
Discov Ther;1(1): 2007, 78-83.
60. Lebovitz H, Melander A, Sulfonyl Ureas: basic aspects and
clinical uses, in: K. Alberti and P. Zimmet, et al. (eds.),
International Textbook of Diabetes Mellitus, 2nd edn., J. Wiley,
Chichester, 1997, 817-840.
61. Massimo MB, Glimepiride in type 2 diabetes mellitus: a review of
the worldwide therapeutic experience. Clin. Ther. 25: 2003,
799-816.
62. Ammar HO, Salama HA, Ghorab M and Mahmoud AA,
Implication of inclusion complexation of glimepiride in
cyclodextrin–polymer systems on its dissolution, stability and
therapeutic efficacy, International Journal of Pharmaceutics,
320 (1-2): 2006, 53-57.
63. Cho CW, Choi JS, Yang KH, Shin SC, Enhanced transdermal
controlled delivery of glimepiride from the ethylene-vinyl acetate
matrix, Drug Deliv. 16(6): 2009, 320-30.
271
64. Ammar HO, Salama HA, El-Nahhas SA, Elmotasem H, Design
and evaluation of chitosan films for transdermal delivery of
glimepiride, Curr Drug Deliv. 5(4): 2008, 290-8.
65. Yao Xue, Zhang Y, Xu DH, Ma Z, Chen Y, Zhao JJ, Xu SB,
Preparation and evaluation In vivo and In vitro of glimepiride
gel-matrix controlled-release patch, Acta pharmaceutica
Sinica;39(8): 2004, 640-4.
66. Nitya Anand. Natural products in India and their
applications. The Eastern Pharmacist; 28(329): 1985, 55.
67. Norman R Farnsworth. A computerized data base for
medicinal plants. The Eastern Pharmacist; 28(326): 1985,
53.
68. Naik SR. Plant derived drugs. The Eastern Pharmacist,
29(346): 1986, 35-40.
69. Handa SS. Future trends of plants as drugs. Pharmatimes,
23(4): 1991, 13-23.
70. Macleod, Edwards, Bouchier, Davidson‘s Principles and
Practice of Medicine. 15th edn. 1987, 461.
71. Ayesha Noor, Gunasekaran S, Soosai A, Manickam and
Vijayalakshmi MA, Antidiabetic activity of Aloe vera and
histology of organs in streptozotocininduced diabetic rats,
Current Science, 94 (8), 2008.
272
72. Grover JK, Yadav S, Vats V. Medicinal plants of India with
anti-diabetic potential, Journal of Ethnopharmacology, 81:
2002, 81-100.
73. Hidehiko Beppu, Yohichi Nagamura, Keisuke,
Hypoglycaemic and antidiabetic effects in mice of Aloe
arborescens Miller var. natalensis Berger, Phytotherapy
Research, 7 (7): 1993, S37–S423.
74. Subbiah Rajasekaran, Kasiappan Ravi, Karuran
Sivagnanam and Sorimuthu Subramanian, Beneficial
Effects Of Aloe Vera Leaf Gel Extract On Lipid Profile
Status In Rats With Streptozotocin Diabetes, Clinical and
Experimental Pharmacology and Physiology, 33: 2006,
232–237.
75. Al Awadi FM: Studies on the activity of individual plants of
anantidiabetic plant mixture. Acta Diabetol Lab. 24 (1),
1987, 159-164.
76. Josias Hamman, Composition and Applications of Aloe vera
Leaf Gel, Molecules, 13: 2008, 1599-1616.
77. Akira Yagi, Sahar Hegazy, Amal Kabbash and Engy Abd-El
Wahab, Possible Hypoglycemic Effect Of Aloe Vera L. High
Molecular Weight Fractions On Type 2 Diabetic Patients, Saudi
Pharmaceutical Journal, 17 (3): 2009, 210-18.
273
78. Agarry OO, Olaleye MT and Bello Michael CO, Comparative
antimicrobial activities of aloe vera gel and leaf, African Journal
of Biotechnology, 4 (12): 2005, 1413-1414.
79. Dilip George, Sham SB, Beena Antony, Comparative evaluation
of the antimicrobial efficacy of aloe vera tooth gel and two
popular commercial toothpastes: An in vitro study, General
Dentistry, 2008, 238-241.
80. Arun kumar S and Muthuselvam M, Analysis of Phytochemical
Constituents and Antimicrobial Activities of Aloe vera L. Against
Clinical Pathogens, World Journal of Agricultural Sciences 5 (5):
2008, 572-576.
81. Saeed MA, Ishtiaq Ahmad, Uzma Yaqub, Shazia Akbar, Amran
Waheed, Saleem M and Nasiruddin. Aloe Vera: A Plant Of Vital
Significance, Science Vision, 9 (1-2): 2004, 1-13.
82. Hidehiko Beppu, Kan Shimpo, Takeshi Chihara, Takaaki
Kaneko, Ikuko Tamai, Sachiyo Yamaji, Sayaka Ozaki, Hiroshi
Kuzuya and Shigeru Sonoda, Antidiabetic effects of dietary
administration of Aloe arborescens Miller components on
multiple low-dose streptozotocin-induced diabetes in mice:
Investigation on hypoglycemic action and systemic absorption
dynamics of aloe components, Journal of Ethnopharmacology,
103 (3): 2006, 468-477.
83. Ljubica Harhajia, Sanja Mijatovica, Danijela Maksimovic-
Ivanica, Dusan Popadicb, Aleksandra Isakovicc, Biljana
Todorovic-Markovicd and Vladimir, Aloe emodin inhibits the
274
cytotoxic action of tumor necrosis factor, European Journal of
Pharmacology, 568 (1-3): 2007, 248-259.
84. Chithra P, Sajithlal GB, Gowri Chandrakasan, Influence of aloe
vera on the healing of dermal wounds in diabetic rats, Journal
of Ethnopharmacology, 59: 1998, 195–201.
85. Po Lin Kuo, Ta Chen Lin, Chun Ching Lin, The antiproliferative
activity of aloe-emodin is through p53-dependent and p21-
dependent apoptotic pathway in human hepatoma cell lines,
Life Sciences, 71: 2002, 1879–1892.
86. Paolo Lissoni, Franco Rovelli, Fernando Brivio, Romano Zago,
Massimo Colciago, Giuseppina Messina, Adelio Mora and
Giorgio Porro, A Randomized Study of Chemotherapy Versus
Biochemotherapy with Chemotherapy plus Aloe arborescens in
Patients with Metastatic Cancer, in vivo 23: 2009, 171-176.
87. Acevedo-Duncan M, Russell C, Patel S, Patel R, Aloe –emodin a
noval antitumor chemotherapeutic drug, International
Immunopharmacology, 4(14): 2004, 1775-1784.
88. Louise Colea and Charles Heard, Skin permeation enhancement
potential of Aloe Vera and a proposed mechanism of action
based upon size exclusion and pull effect, International Journal
of Pharmaceutics, 333 (1-2), 2007, 10-16.
89. Chou TH, Liang CH and Sakr AM, The molecular effects of aloe-
emodin (AE)/liposome-AE on human nonmelanoma skin cancer
cells and skin permeation, Chem Res Toxicol. 22(12): 2009,
2017-28.
275
90. Elsabbagh HM. Evaluation of guar gum as a tablet additive: a
preliminary report. Pharm Ind, 39(4): 1977, 399-403.
91. Duru C. A comparative study of the disintegrating efficiency of
polysaccharides in a directly-tabletable formulation.
Pharmaceut Technol Int, 4(5): 1992, 15, 16, 20, 22 and 23.
92. Adkin DA, Kenyon CJ, Lerner EI, Landau I, Wilding IR, et al.
Use of scintigraphy to provide proof of concept for novel
polysaccharide preparations designed for colonic drug delivery.
Pharm Res; 1, 1997 103-107.
93. Wong D, Larrabee S, Clifford K, Tremblay J, Friend DN. USP
Dissolution Apparatus II for screening of guar based colonic
delivery formulations. J Controlled Release; 47: 1997, 173-179.
94. Goldstein AM, Alter EN, Seaman JK. Guar gum. Industrial
Gums, 2nd edition. New York: Academic Press, 1973: 303-321.
95. Vemuri S. Flow and consistency index dependence of
pseudoplastic guar gum solutions. Drug Dev Ind Pharm; 14:
1988, 905-914.
96. Chaurasia M, Chourasia MK, Jain NK, Jain A, Soni V, Gupta Y,
Jain SK. Cross-Linked Guar Gum Microspheres: A Viable
Approach for Improved Delivery of Anticancer Drugs for the
Treatment of Colorectal Cancer. AAPS Pharm SciTech.; 7(3):
2006, Article 74.
97. Al-Saidan SM, Krishnaiah YS, Patro SS, Satyanaryana V. In vitro
and In vivo Evaluation of Guar Gum Matrix Tablets for Oral
276
Controlled Release of Water-soluble Diltiazem Hydrochloride.
AAPS PharmSciTech.; 06(01): 2005, E14-E21
98. Udaya S. Toti and Tejraj M. Aminabhavi, Modified guar gum
matrix tablet for controlled release of diltiazem hydrochloride,
Journal of Controlled Release, 95 (3), 2004, 567-577.
99. Krishnaiah YSR, Karthikeyan RS, Gouri Sankar V,
Satyanarayana V. Three-layer guar gum matrix tablet
formulations for oral controlled delivery of highly soluble
trimetazidine dihydrochloride, Journal of Controlled Release, 81
(1): 2002, 45-56.
100. Senapati MK, Srinath A, JK Pandit, In vitro release
characteristics of matrix tablets: Study of Karaya gum and Guar
gum as release modulators, Indian Journal of Pharmaceutical
Scinces, 68 (6): 2006, 824-826.
101. Krishanaiah YSR, Development of Colon targeted oral guar
matrix tablets of albendazole for the treatment of helminthiasis
B3 adrenoceptors, an overview, Indian journal of
Pharmaceutical Scinces, 65 (4); 2003, 378-385.
102. Baweja JM, Misra AN, Studies on kinetics of drug release from
modified guar gum hydrophilic matrices, Indian journal of
Pharmaceutical Sciences: 59 (6): 1997, 316-320.
103. Deshmukh VN, Jadhav JK, Sakarkar DM, Formulation and In
vitro evaluation of theophylline anhydrous bioadhesive tablets,
Asian Journal of Pharmaceutics, 3 (1): 2007, 54-58.
277
104. Stubberud L, Arwidsson HG, Hjortsberg V, Graffner C. Water-
solid interactions. Part 3. Effect of glass transition temperature,
Tg and processing on tensile strength of compacts of lactose and
lactose/polyvinyl pyrrolidone. Pharm Dev Technol; 1(2): 1996,
195-204.
105. Iwata M, Ueda H. Dissolution properties of glibenclamide in
combinations with polyvinylpyrrolidone. Drug Dev Ind Pharm;
22: 1996, 1161-1165.
106. Wessel W, Schoog M, Winkler E. Polyvinylpyrrolidone (PVP), its
diagnostic, therapeutic and technical application and
consequences thereof. Arzneimittelforschung; 21: 1971, 1468-
1482.
107. Horn D, Ditter W. Chromatographic study of interactions
between polyvinylpyrrolidone and drugs. J Pharm Sci; 71: 1982,
1021-1026.
108. Hsiao CH, Rhodes HJ, Blake MI. Fluorescent probe study of
sulfonamide binding to povidone. J Pharm Sci; 66: 1977, 1157-
1159.
109. Jager KF, Bauer KH. Polymer blends from PVP as a means to
optimize properties of fluidized bed granulates and tablets. Acta
Pharm Technol; 30(1): 1984, 85-92.
110. Robinson BV, Sullivan FM, Borzelleca JF, Schwartz SL. PVP: A
Critical Review of the Kinetics and Toxicology of
Polyvinylpyrrolidone (Povidone). Chelsea, MI: Lewis Publishers,
1990.
278
111. Rao PR, Diwan PV, Drug diffusion from cellulose acetate-
polyvinyl pyrrolidone free films for transdermal administration,
Indian journal of Pharmaceutical Sciences, 58: 6, 1996, 246-
250.
112. Santanu Ghosh and Barik BB, Preparation and evaluation of
aceclofenac sustained release formulation and comparison of
formulated and marketed product, International Journal of
Medicine and Medical Sciences, 1 (9): 2009, 375-382.
113. Draganoiu Elena, Andheria Mahalaxmi, Adel SAKR. Evaluation
of the new polyvinylacetate/ povidone excipient for matrix
sustained release dosage forms, Pharmazeutische Industrie, 63
(6), 2001, 624-629.
114. Raghavendra Rao NG, Gandhi Sagar, Patel Tarun, Formulation
And Evaluation Of Sustained Release Matrix Tablets Of
Tramadol Hydrochloride, International Journal of Pharmacy and
Pharmaceutical Sciences, 1 (1), 2009, 60-70.
115. Sahoo J, Murthy PN, Biswal S and Manik, Formulation of
Sustained-Release Dosage Form of Verapamil Hydrochloride by
Solid Dispersion Technique Using Eudragit RLPO or Kollidon
SR, AAPS PharmSciTech. 10(1): 2009, 27–33.
116. Biswajit Mukherjeea, Sushmit a Mahapatraa, Ritu Guptab,
Balaram Patraa, Amit Tiwarib,Priyanka Arora..A comparison
between povidone-ethylcellulose and povidone-eudragit
Transdermal dexamethasone matrix patches based on In vitro
279
skin permeation. European Journal of Pharmaceutics and
Biopharmaceutics, 59, 2005, 475–483.
117. Nithiyananthan TS, Shankarananth V, Rajasekhar KK, Hareesh
G, Formulation And Evaluation Of Tamsulosin Hydrochloride As
Sustained Release Matrix Tablet, International Journal of
ChemTech Research, 1 (4): 2009, 1278-1290.
118. Satyavati GV, Raina MK, Sharma M. (Eds.) Medicinal plants of
India, Vol.1. Indian Council of Medical Research, New Delhi,
1976.
119. Subramanian PM, Misra GS, Chemical constituents of Ficus
bengalensis (Part II) Pol J Pharmacol; 30: 1978, 559-62.
120. Rimi Shukla, Kiran Anand, Prabhu KM, Suryanarayana Murthy
P, Hypoglycaemic Effect of the Water Extract of Ficus
Bengalensis in Alloxan Recovered, Mildly Diabetic and Severely
Diabetic Rabbits, Int. J. Diab. Dev. Countries, 14, 1994, 78-81
121. Rakesh Kumar Singh, Shikha Mehtaa, Dolly Jaiswala, Prashant
Kumar Raia and Geeta Wata, Antidiabetic effect of Ficus
bengalensis aerial roots in experimental animals, Journal of
Ethnopharmacology, 123 (1): 2009, 110-114.
122. Singh RK, Mehta S, Jaiswal D, Rai PK, Watal G. Antidiabetic
effect of Ficus bengalensis aerial roots in experimental animals,
J Ethnopharmacol. 123(1): 2009, 110-4.
123. Kumar RV and Augusti KT. Antidiabetic effect of a leucocyanidin
derivative isolated from the bark of Ficus bengalensis Linn. Ind
J Biochem Biophys; 26: 1989, 400-4.
280
124. Cherian S, Augusti KT. Antidiabetic effect of glycoside of
leucopelargonidin isolated from Ficus bengalensis Linn. Ind J
Exp Biol; 31: 1993, 26-9
125. Mahalingam Gayathri and Krishnan Kannabiran, antidiabetic
and ameliorative potential of Ficus bengalensis bark Extract in
streptozotocin induced diabetic rats, Indian Journal of Clinical
Biochemistry, 23 (4), 2007, 394-400
126. Shukla R, Anand K, Prabhu KM, Murthy PS.
Hypocholesterolemic effect of water extracts of the bark of
Banyan tree, Ficus bengalensis. Ind J Clin Biochem; 10: 1995,
14–18.
127. Daniel RS, Mathew BC, Devi KS, Augusti KT. Antioxidant effect
of two flavonoids from the bark of Ficus bengalensis Linn in
hyperlipidemic rats, Indian J Exp Biol. 36(9), 1998, 902-6.
128. Vinson, Joe A. Functional Food Properties of Figs. Cereal Foods
World, 44 (2):1999, 82-87.
129. Gibernau M., Buser HR, Frey JE and Hossaert MM. Volatile
compounds from extracts of figs of Ficus carica. Phytochem, 46:
1997, 241.
130. Blodgett EC and Belgin Gomec. Fig mosaic. Plant Dis. Reptr. 51:
1967, 893-896.
131. Burnett HC. Species of Ficus susceptible to the fig mosaic virus.
Proc. Florida State Hort. Soc. 73: 1960, 316-320.
132. Krishna Mohan G, Pallavi E, Ravi Kumar B, Ramesh M,
Venkatesh S. Hepatoprotective activity of Ficus carica Linn. leaf
281
extract against carbon tetrachloride-induced hepatotoxicity in
rats, DARU, 15 (3), 2007, 162-166.
133. Gond NY and Khadabadi SS, Hepatoprotective activity of Ficus
carica leaf extract on Rifampicin induced hepatic damagein rats,
indian Journal of Pharmacceutical Sciences, 2008, 364-366
134. Vinson Joe A, Zubik, Ligia, Bose, Pratima, Samman, Najwa and
Proch, John. Dried Fruits: Excellent In vitro and In vivo
Antioxidants. J. Am. Coll. Nutr. 24(1): 2005, 44-50.
135. Rahman NN, Khan M and Hasan R, Bioactive components from
Ficus glomerata, Pure & App/. Chem., 66 (10, 11), 1994, 2287-
2290.
136. Kirtikar KR and Basu BD. Indian Medicinal Plants, vol. 3, 2nd
edn. Bishen Singh Mahandra Pal Singh, Dehra Dun, 1975,
2327–2328.
137. Temsiririrkkul R, Promjid S, Sowwanee S, Tana K, Wongsatid C
and Paritas T. Herbal Taxonomy, Pharmacognosy Faculty
Pharmaceutical Science Mahidol University, 16, 1983, 45.
138. Suresh C, Jawahar L, Sabir M. Chemical examination of the
fruits of Ficus glomerata Roxb. Journal of the Indian Chemical
Society. 56 (12), 1979, 1269.
139. Satyavati GV, Raina MK, Sharma M. Medicinal Plants of India,
Indian Council of Medical Research, New Delhi, 1, 1976, 415-
421.
140. Muhammad Shoaib Akhtar and Abdel Qayum Qureshi,
Phytopharmacological Evaluation of Ficus Glomerata, Roxb.
282
Fruit for Hypoglycaemic Activity in Normal and Diabetic
Rabbits, Pakistan J. Pharm. Sci.1 (2): 1988, 87-96.
141. Rao CV, Verma AR, Vijayakumar M and Rastogi S.
Gastroprotective effect of standardized extract of Ficus
glomerata fruit on experimental gastric ulcers in rats. Journal of
Ethnopharmacology. 115 (2), 2008, 323-326.
142. Joshi Uttara and Upadhye Mohini, Evaluation of Antioxidant
Activity of Aqueous Extract Bark of Ficus glomerata, Research
J. Pharm. and Tech. 1(4): 2008, 537-538.
143. Bheemachari J, Ashok K, Joshi NH, Suresh DK and Gupta
VRM, Antidiarrhoeal Evaluation of Ficus racemosa LINN., Latex,
Acta Pharmaceutica Sciencia 49:2007, 133 -138.
144. Omray A, Omray P. Evaluation of microcrystalline cellulose as a
glidant. Indian J Pharm Sci; 48: 1986, 20-22.
145. Dittgen M, Fricke S, Gerecke H. Microcrystalline cellulose in
direct tabletting. Mfg Chem; 64(7): 1993, 17, 19, 21.
146. Landin M, Martinez-Pacheco R, Gomez-Amoza JL, Souto C,
Concheiro A, Rowe RC. Effect of country of origin on the
properties of microcrystalline cellulose. Int J Pharmaceutics; 91:
1993, 123-131.
147. Rowe RC, McKillop AG, Bray D. The effect of batch and source
variation on the crystallinity of microcrystalline cellulose. Int J
Pharmaceutics; 101: 1994, 169-172.
148. Staniforth JN, Baichwal AR, Hart JP, Heng PWS. Effect of
addition of water on the rheological and mechanical properties
283
of microcrystalline celluloses. Int J Pharmaceutics; 41: 1988,
231-236.
149. Phadke DS, Collier JL. Effect of degassing temperature on the
specific surface area and other physical properties of
magnesium stearate. Drug Dev Ind Pharm; 20 (5): 1994, 853-
858.
150. Marwaha SB, Rubinstein MH. Structure-lubricity evaluation of
magnesium stearate. Int J Pharmaceutics; 43 (3): 1988, 249-
255.
151. Desai DS, Rubitski BA, Varia, Newman AW. Physical
interactions of magnesium stearate with starch-derived
disintegrants and their effects on capsule and tablet dissolution.
Int J Pharmaceutics; 91(2-3): 1993, 217-226.
152. Butcher AE, Jones TM. Some physical characteristics of
magnesium stearate J Pharm Pharmacol; 24: 1972, 1-9.
153. Johansson ME. Granular magnesium stearate as a lubricant in
tablet formulations. Int J Pharmaceutics; 21, 1984, 307-315.
154. Manjunatha KM, Ramana MV, Satyanarayana, Design and
evaluation of diclofenac sodium controlled drug delivery
systems, Indian Journal of Pharmaceutical Sciences; 69 (3),
2007, 384-389 .
155. Mohammad Reza Siahi, Mohammad Barzegar-Jalali, Farnaz
Monajjemzadeh, Design and Evaluation of 1- and 3-Layer
Matrices of Verapamil Hydrochloride for Sustaining Its Release,
AAPS PharmSciTech; 6 (4): 2005, 626- 632, Article 77.
284
156. Bhupinder Singh, Sukhwinder Kaur Chakkal and Naveen
Ahuja, Formulation and Optimization of Controlled Release
Mucoadhesive Tablets of Atenolol Using Response Surface
Methodology. AAPS Pharm Sci Tech. 7 (1): 2006, Article 3.
157. Sourabh Jain, Yadav SK and UK Patil. Preparation and
Evaluation of Sustained Release Matrix Tablet of Furosemide
using Natural Polymers, Research J. Pharm. and Tech. 1 (4):
2008, 374-376.
158. Selim Reza M , Mohiuddin Abdul Quadir, Syed Shabbir Haider,
Comparative evaluation of plastic, hydrophobic and hydrophilic
polymers as matrices for controlled-release drug delivery,
Journal of Pharmacy and Pharmaceutical Science, 6 (2): 2003,
282-291.
159. Panna Thapa, Manish Ghimire, Alex B. Mullen and Howard N.E.
Stevens, controlled release oral delivery system containingwater
insoluble drug, kathmandu university journal of science,
engineering and technology, 1 (1): 2005, 1-10.
160. Gedela V, Murali Mohan Babu, Namballa RK, Kasina HS, Battu
JR, Namburu KK and Kolapalli VRM. In vivo Evaluation of
Modified Gum Karaya as a Carrier for Improving the Oral
Bioavailability of a Poorly Water Soluble Nimodipine, AAPS
Pharm SciTech, 2002; 3.
161. Martins OE, Olobayo OK, Sabinus O. Effect of the molecular size
of carboxy methyl cellulose and some polymers on the sustained
285
release and some polymers on the sustained release, Acta
Pharm. 56: 2006, 325–335.
162. Evelyn Ojoe, Edna Mitie Miyauchi, Tais Cobo Viviani, Vladi Olga
Consiglieri, Formulation and In vitro evaluation of theophylline
Eudragit sustainedrelease tablets, Revista Brasileira de Ciências
Farmacêuticas Brazilian Journal of Pharmaceutical Sciences, 41
(3), 2005,159-167.
163. Jonnalagadda S, Robinson DH. A Bioresorbable, Polylactide
Reservoir for Diffusional and Osmotically Controlled Drug
Delivery. AAPS Pharm SciTech, 1 (4), 2000, article 29.
164. Perioli L, Ambrogi V, Giovagnoli S, Ricci M, Blasi P, Rossi C.
Mucoadhesive Bilayered Tablets for Buccal Sustained Release of
Flurbiprofen. AAPS Pharm SciTech. 8 (3), 2007, Article 54.
165. Manjunatha KM, Ramana MV, Satyanarayana D, Design and
evaluation of diclofenac sodium controlled drug delivery
systems: 69 (3), 2007, 384-389.
166. Tiwari SB, Murthy TK, Pai MR, Mehta PR, Chowdary PB.
Controlled Release Formulation of Tramadol Hydrochloride
Using Hydrophilic and Hydrophobic Matrix System. AAPS
Pharm SciTech, 4 (3), 2003, article 31.
167. Rani M, Mishra B. Comparative In vitro and In vivo Evaluation
of Matrix, Osmotic Matrix, and Osmotic Pump Tablets for
Controlled Delivery of Diclofenac Sodium. AAPS Pharm SciTech,
5 (4), 2004, article 71.
286
168. Avachat A, Kotwal V. Design and Evaluation of Matrix-Based
Controlled Release Tablets of Diclofenac Sodium and
Chondroitin Sulphate. AAPS Pharm SciTech, 8 (4), 2007, Article
88.
169. Yeole PG, Galgatte UC, Babla IB, Nakhat PD, Design and
evaluation of Xanthan gum-based sustained release Matrix
tablets of Diclofenac sodium, 68 (2), 2006, 185-189.
170. Kondaiah A and Prakash K. Design of controlled release non-
erodible polymeric matrix tablets of theophylline using sintering
technique, Indian Journal of Pharmaceutical Sciences, 64 (3),
2002, 239-43.
171. Kuksal A, Tiwary AK, Jain NK, Jain S. Formulation and In vitro,
In vivo Evaluation of Extended- release Matrix Tablet of
Zidovudine: Influence of Combination of Hydrophilic and
Hydrophobic Matrix Formers. AAPS PharmSciTech, 7(1): 2006;
Article 1.
172. Abdelkader H, Abdalla OY, Salem H. Formulation of Controlled-
Release Baclofen Matrix Tablets: Influence of Some Hydrophilic
Polymers on the Release Rate and In vitro Evaluation. AAPS
Pharm SciTech, 8 (4), 2007, Article 100.
173. Patel VM, Prajapati BG, Patel MM, Formulation, Evaluation, and
Comparison of Bilayered and Multilayered Mucoadhesive Buccal
Devices of Propranolol Hydrochloride. AAPS Pharm SciTech, 8
(1), 2007, Article 22.
287
174. Jaber Emami, Naser Tavakoli, Formulation of sustained release
lithium carbonate matrix tablets: influence of hydrophilic
materials on the release rate and In vitro -In vivo evaluation. J
Pharm Pharmaceut Sci, 7 (3), 2005, 338-344.
175. Dave BS, Amin AF, Patel MM. Gastroretentive Drug Delivery
System of Ranitidine Hydrochloride: Formulation and In vitro
Evaluation. AAPS Pharm SciTech, 5 (2), 2004, article 34.
176. Al-Taani BM, Tashtoush BM. Effect of Microenvironment pH of
Swellable and Erodable Buffered Matrices on the Release
Characteristics of Diclofenac Sodium. AAPS Pharm SciTech, 4
(3), 2003, article 43.
177. Reddy KR, Mutalik S, Reddy S. Once-Daily Sustained-Release
Matrix Tablets of Nicorandil: Formulation and In vitro
Evaluation. AAPS PharmSciTech, 4 (4), 2003, article 61.
178. Piyakulawat P, Praphairaksit N, Chantarasiri N, Muangsin N.
Preparation and Evaluation of Chitosan/Carrageenan Beads for
Controlled Release of Sodium Diclofenac. AAPS Pharm SciTech,
8 (4), 2007, Article 97.
179. Bhalekar MR, Avari J, Umalkar RA, Preparation and In vitro
evaluation of sustained release drug delivery system for
verapamil HCL, Indian Journal of Pharmaceutical Scinces, 69
(3), 2007, 418-422.
180. Arora P, Mukherjee B. Design, development, physicochemical,
and In vitro and In vivo evaluation of transdermal patches
288
containing diclofenac diethylammonium salt. J Pharm Sci. 91
(9), 2002, 2076-89.
181. Bendas ER, Tadros MI. Enhanced Transdermal Delivery of
Salbutamol Sulfate via Ethosomes. AAPS Pharm SciTech. 8 (4),
2007, Article 107.
182. Bagyalakshmi Janardhanan, Vamsikrishna RP, Manavalan R,
Ravi TK, Manna PK. Formulation Development and In vitro and
In vivo Evaluation of Membrane-Moderated Transdermal
Systems of Ampicillin Sodium in Ethanol: pH 4.7 Buffer Solvent
System. AAPS Pharm SciTech. 8 (1), 2007, Article 7.
183. Deepak G, Pundarikakshudu K., Formulation and Pharmaco-
technical Evaluation of Controlled Release Transdermal Delivery
System of Bupropion. AAPS Pharm SciTech. 4 (1), 2003, article
3.
184. Pandey S, Praveen SH, Udupa N, Formulation and evaluation of
nimesulide transdermal drug delivery systems, Indian Journal
of Pharmaceutical Sciences, 62 (5), 2000, 376-379.
185. Agrawal SS, Munjal Priya, Permeation studies of atenolol and
metoprolol tartrate from three different polymer matrices for
transdermal delivery, Indian Journal of Pharmaceutical
Sciences; 69 (4): 2007, 535-539.
186. Shakeel F, Baboota S, Ahuja A, Ali J, Aqil M, Shafiq S.
Nanoemulsions as Vehicles for Transdermal Delivery of
Aceclofenac. AAPS Pharm SciTech, 8 (4), 2007, Article 104.
289
187. Murthy SN, Rani S, Hiremath R. Physical and Chemical
Permeation Enhancers in Transdermal Delivery of Terbutaline
Sulphate. AAPS Pharm SciTech. 2 (1), 2001, article 8.
188. Parikh DK, Ghosh TK, Feasibility of Transdermal Delivery of
Fluoxetine. AAPS Pharm SciTech. 6 (2), 2005, 144-149.
189. Sarıgullu Ozguney I, Yeşim Karasulu H, Kantarcı G, Sozer S,
Guneri T, and Ertan G. Transdermal Delivery of Diclofenac
Sodium Through Rat Skin From Various Formulations. AAPS
Pharm SciTech. 7 (4), 2006, Article 88.
190. Aqil M, Ali A, Sultana Y, Dubey K, Najmi AK, Pillai KK. In vivo
Characterization of Monolithic Matrix Type Transdermal Drug
Delivery Systems of Pinacidil Monohydrate: A Technical Note.
AAPS Pharm SciTech. 7 (1), 2006, Article 6.
191. Satturwar PM, Fulzele SV, Dorle AK, Evaluation of Polymerized
Rosin for the Formulation and Development of Transdermal
Drug Delivery System: A Technical Note. AAPS Pharm SciTech.
6 (4), 2005, 649-654.
192. Narasimha Murthy S and Shobha Rani, Physical and Chemical
Permeation Enhancers in Transdermal Delivery of Terbutaline
Sulphate, 2000, AAPS Pharm SciTech, 2 (1), 2001, Technical
Note1.
193. Malay KD and Saroj KG. Ex vivo and In vivo evaluation of
transdermal formulation of trazodone hydrochloride, Acta
Poloniae Pharmaceutica and Drug Research, 65 (4), 2008, 481-
486.
290
194. Yuveraj Singh Tanwar, Chetan Singh, Development and
evaluation of carvedilol transdermal patches, Acta Pharm. 57,
2007, 151–159.
195. Ting Li, Changshun Ren, Manli Wang, Ligang Zhao, Ximeng
Wang, Liang Fang, Optimized preparation and evaluation of
indomethacin transdermal patch, Asian Journal of
Pharmaceutical Sciences, 2 (6): 2007, 249-259.
196. Srinivas mutallik, Udupa N, Formulation development, In vitro
and In vivo evaluation of membrane controlled transdermal
systems of Glibenclamide, Journal of Pharmaceutical Sciences,
8 (1): 2005, 26-38.
197. Ekapol Limpongsa and Kraisri Umprayn, Preparation and
Evaluation of Diltiazem Hydrochloride Diffusion-Controlled
Transdermal Delivery System, AAPS PharmSciTech. 9(2): 2008,
464–470.
198. Ubaidulla U, Reddy MV, Ruckmani K, Ahmad FJ, Khar RK.
Transdermal System of Carvedilol: Effect of Hydrophilic and
Hydrophobic Matrix on In vitro and In vivo Characteristics. AAPS
Pharm SciTech, 8 (1), 2001, Article 2S.
199. Sridevi MG, Chary DR, Krishna P and Diwan V.
Pharmacodynamic evaluation of transdermal drug delivery
system of glibenclamide in rats, Indian Journal of
Pharmacology, 32: 2000, 309-312.
291
200. The United States Pharmacopeia 27/The National Formulary
22, United States Pharmacopeial Convention, Asian Ed, 2004,
867.
201. Glicksman, M. In Gum Technology in the Food Indmry 1969,
Ch. 14, p. 509, London, Academic Press.
202. Mark L. Woolfe, a Martin F. Chaplid and Gifty Otchere, Studies
on the Mucilages Extracted from Okra Fruits (Hibiscus
esculentus L.) and Baobab Leaves (Adansonia digitata L.), J.
Sci. Fd Agric. 28, 1917, 519-529.
203. Lippincott Williams and wilkins, Remington, The science and
Practice of pharmacy, 21st edition, vol. I, 223,305, 320,756.
204. Anonymous, British Pharmacopoeia, Vol. II, 2000, A – 207 , 210
.
205. Khandelwal KR, ―Practical Pharmacognosy‖,12th edition, Nirali
prakashan, Pune, 2004,149,153,156, 157.
206. Anonymous, Quality control methods for medicinal plant
materials, World Health Organization Geneva 1998, 8.
207. Indian pharmacopoeia, 4th edition, ministry of Health and
Family welfare, Govt. of India, controller of publication, New
Delhi 1996, A- 35,37,54,89,97,109.
208. United State Pharmacopoeia, TWIN Brook Park Way, Rockville,
MD, 24, 1954, 731.
209. Lachman, L. et al. The Theory and practice of industrial
pharmacy, 4th edition, varghise publishing house, Bombay
1987, 243.
292
210. Ravin LJ and Radebaugh GW, ―Preformulation‖, Chapter 75 in
Remington‘s Pharmaceutical Sciences, 18th edition, Mack
Publishing Company, Easton, Pennsylvania, 1990.
211. Official Monographs in Indian Pharmacopoeia, Ministry of
health and welfare, Delhi, Controller of publication; 1996.
212. The United State Pharmacopoeia 24, NF 19, United state
pharmacopoeial convention, Rockville, M.D. Asian Edi., 2000
213. Banker G and Rhodes CT, Modern Pharmaceutics, Marcel
Dekker, Inc., 2000.
214. Fiese EF and Hagen TA, ―Preformulation‖, Chapter 8 in the
Theory and Practice of Industrial Pharmacy, Lea & Febiger,
Philadelphia, 1986.
215. Saleh M. Al-Saidan, Yellela S.R. Krishnaiah, Srinivas S. Patro
and Vemulapalli Satyanaryana, In vitro and In vivo Evaluation of
Guar Gum Matrix Tablets for Oral Controlled Release of Water-
soluble Diltiazem Hydrochloride, AAPS Pharm SciTech. 6 (1),
2005, Article 5
216. Rajesh KS, Venkataraju MP And Gowda DV, Effect Of
Hydrophilic Natural Gums In Formulation Of Oral-Controlled
Release Matrix Tablets Of Propranolol Hydrochloride, Pak. J.
Pharm. Sci. 22 (2): 2009, 211-219.
217. Verma PRP and Chandak AR: Development of matrix controlled
transdermal delivery systems of pentazocine: In vitro/In vivo
performance, Acta Pharm. 59, 2009, 171–186.
293
218. Aqil M, Ali A. Monilithic matrix type transdermal drug delivery
systems of 119 pinacidil monohydrate: In vitro characterization.
Eur J Pharm Biopharm, 4, 2002, 161-164.
219. Martin A, Micromeritics, Physical Pharmacy. 4th ed.
Philadelphia: Lippincott Williams & Wilkins; 2001; 423-52.
220. Lachman L, Lieberman HA, Kanig JL. The Theory and Practice
of Industrial Pharmacy. 4th edition, Philadelphia: PA: Lea &
Febiger; 1986; 293-45.
221. Cooper J, Gunn C. Powder flow and compaction. In: Carter SJ,
eds. Tutorial Pharmacy. New Delhi, India: CBS Publishers and
Distributors; 1986: 211-233.
222. Aulton ME, Wells TI. Pharmaceutics: The Science of Dosage
Form Design. London, England: Churchill Livingstone; 1988.
223. Andreopoulos AG and Tarantili PA, J. Biomed. Appl., 2001, 16,
35.
224. Martindale: The Extra Pharmacopoeia, 31st Edn., The
Pharmaceutical Press, London, 1996, 1588.
225. The United States Pharmacopeia, XXIII. Rockville, MD: United
States Pharmacopeial Convention, Inc; 1995:801.
226. RC Rowe, PJ Sheskey, PJ Weller, Handbook of Pharmaceutical
Excipients, 4th ed. London, UK: Royal Pharmaceutical Society of
Great Britain; 2000-120.
227. Lachman LH, Lieberman A, The Theory and Practice of
Industrial Pharmacy, 4th edition, Varghese Publishing House,
Mumbai:2000;296-300
294
228. Killedar SG, Bhagwat DA, Adnaik RS, More HN and D‘souza JI.
optimization of method for determination of swelling factor of
Ispaghula husk seeds, Indian Drugs 45 (4)April 2008, 310–313.
229. Chalk JB, Patterson M, Smith MT, Eadie MJ. Correlations
between In vitro dissolution, In vivo bioavailability and
hypoglycaemic effect of oral glibenclamide. Eur J Clin
Pharmacol. 31 (2), 1986, 177–182.
230. Balant L, Fabre J, Zahnd GR. Comparison of the
pharmacokinetics of glipizide and glibenclamide in man. Eur J
Clin Pharmacol. 8 (1): 1975, 63–69.
231. Coppack SW et al, Pharmacokinetic and pharmacodynamic
studies of glibenclamide in non-insulin dependent diabetes
mellitus, Br J Clin Pharmacol; 29 (6): 1990, 673–684.
232. Ferner RE, Chaplin S. The relationship between the
pharmacokinetics and pharmacodynamic effects of oral
hypoglycaemic drugs. Clin Pharmacokinet, 12 (6): 1987, 379–
401.
233. Jing Yaoa, Ya-Qin Shib and Zhuo-Rong Lia Development of a
RP-HPLC method for screening potentially counterfeit anti-
diabetic drugs, Journal of Chromatography B, 853 (1-2): 2007,
254-259.
234. Wahlin-Boll E, Melander A. High-performance liquid
chromatographic determination of glipizide and some other
sulfonylurea drugs in serum. J Chromatogr, 64 (4), 1979, 541–
546.
295
235. Feldman JM. Glyburide: a second-generation sulfonylurea
hypoglycemic agent. History, chemistry, metabolism,
pharmacokinetics, clinical use and adverse effects.
Pharmacotherapy; 5 (2), 1985, 43–62.
236. Kobayashi K, Kimura M, Sakoguchi T, Hase A, Matsuoka A,
Kaneko S. Pharmacokinetics of gliclazide in healthy and diabetic
subjects. J Pharm Sci; 73 (12): 1984, 1684–1687.
237. Remunan C, Bretal M, Nunez A, Bila Jato JL. Accelerated
stability of sustained release tablet prepared with Gelucire. Int J
Pharm; 80: 1992, 151-159.
238. Amnuaikit C, Ikeuchi I, Ogawara K, Higaki K, Kimura T. Skin
permeation of propranolol from polymeric film containing
terpene enhancers for transdermal use, Int. J. Pharm. 289:
2005, 167–178.
239. Verma PRP, Iyer SS. Transdermal delivery of propranolol using
mixed grades of Eudragit: design and in-vitro and In vivo
evaluation. Drug Dev. Ind. Pharm.; 26: 2000, 471–476.
240. Gupta R, Mukherjee B. Development and In vitro evaluation of
Diltiazem hydrochloride transdermal patches based on
povidone-ethyl cellulose matrices. Drug Dev Ind Pharm; 29:
2003, 1-7.
241. Arora P, Mukherjee B. Design, development, physicochemical,
and In vitro and In vivo evaluation of transdermal patches
containing Diclofenac diethylammonium salt. J Pharm Sci 91:
2002, 2076-2089.
296
242. Baichwal MR, Polymer films as drug delivery systems. In:
Advances in drug delivery systems. Bombay, MSR Foundation;
1985, 136-147.
243. Costa P, Morgado R, Sousa Lobo JM. Design and evaluation of a
lorazepam transdermal delivery system, Drug Dev Ind Pharm,
23, 1997, 939-944.
244. Draize JH, Woodward GS, Calvery HO. Method for the study of
irritation and toxicity of substances applied topically to the skin
and mucus membrane. J Pharmacol Exp Ther; 82: 1994, 377-
90.
245. Singh S, Drug stability testing and shelf life determination
according to international guidelines. Pharm Tech, 1999; 23:
68-88.